Scientists probe Gut-Liver link in alcohol and fatty liver cancers
NCT ID NCT03307408
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowledge, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
180 people
The number who actually took part.
- Started
-
Feb 2017
- Finished
-
Sep 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with alcoholic or non-alcoholic fatty liver diseases.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Group 1 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients in the group with metabolic fatty liver with hepatocellular carcinoma * Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice. * No systemic HCC treatment in the previous 6 months Group 2 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients in the group with metabolic fatty liver without hepatocellular carcinoma * Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy in routine practice. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients. Group 3 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients with an alcoholic liver disease with hepatocellular carcinoma * Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice. * No systemic HCC treatment in the previous 6 months Group 4 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients with an alcoholic liver disease without hepatocellular carcinoma * Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy in routine practice. No systemic HCC treatment in the previous 6 months. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcoholic liver disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nice
Nice, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody drug conjugate tested against advanced cancers
- Underactive thyroid may worsen liver scarring in fatty liver disease
- Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
- AI-Enhanced ultrasound aims to catch liver cancer earlier
- Can turbocharged immune cells stop liver cancer from coming back?
- Two blood markers put to the test for early liver cancer detection